Rockwell Medical Reports Q1 2025 Results: Sales Decline Amid Operational Challenges and Losses

Rockwell Medical, Inc. (NASDAQ: RMTI) has reported its financial results for the first quarter of 2025, revealing both challenges and areas for potential improvement as it continues its focus on the hemodialysis market.

Key Financial Highlights:

• Net Sales: $18.9 million for Q1 2025, down 17% from $22.7 million in Q1 2024.
• Gross Profit: $3.0 million, slightly lower than $3.1 million for the same period last year.
• Operating Loss: $1.36 million, compared to $1.32 million in Q1 2024.
• Net Loss: $1.5 million, improved from a net loss of $1.73 million in Q1 2024.
• Cash On Hand: Approximately $11.4 million at the end of Q1 2025, down from $15.7 million at the end of Q4 2024.
• Working Capital: $21.8 million as of March 31, 2025.

Positive Aspects:

• Gross margin improved to 16% from 14% year-over-year.
• Interest expense decreased to $277,000 from $431,000, reflecting better management of debt.
• Improved Comparatively on net loss per share: $0.04 for Q1 2025 down from $0.06 in Q1 2024.

Negative Aspects:

• Significant decline in sales due to loss of volume from major customer DaVita, transitioning to a new supplier, severely impacting total revenues.
• Cash used in operating activities increased to $3.5 million from $2.4 million year-over-year.
• Accrued liabilities have significantly decreased, potentially indicating increased operational inefficiencies or cash pressures.
• Product research and development expenses were virtually absent as the company continues to pause development initiatives.

The management's strategic focus remains on enhancing revenue streams while contending with challenges in customer retention and overall market conditions. The company noted ongoing discussions with DaVita concerning supply continuity amidst concerns around substantial revenue shifts, alongside efforts to potentially engage new customer relationships and strategic partnerships.

Rockwell Medical’s financial trajectory will be crucial in assessing the long-term sustainability, particularly in light of its operating losses and the need for effective capital management moving forward amidst a volatile healthcare market landscape. As the company navigates these dynamics, monitoring its operational adjustments and potential fundraising activities will be essential.

For more detailed information, refer to their latest [SEC Filing](https://www.sec.gov/Archives/edgar/data/1041024/000162828025024434/rmti-20250331.htm).